000			05509cam a2200433Mi 4500
001			96410
003			ES-MaUEC
005			20230102112752.0
006			m o d
007			cr cnu---unuuu
008			170812s2017 xx o 000 0 eng d
020			_a3319595040 _q(electronic bk.)
020			_a9783319595047 _q(electronic bk.)
020			_z3319595032
020			_z9783319595030
040			_aEBLCP _cEBLCP _dYDX _dN$T _dGW5XE _dDKU _dOCLCF _dUAB _dAZU _dOCLCQ _dUPM _dMERER _dOCLCQ _dESU _dIOG _dCOO _dES-MaUEC _bspa
050		4	_aRM151 _b2017 EB
100	1		_aTrottet, Lionel.
245	1	0	_aDermal drug selection and development : _ban industrial perspective _cLionel Trottet, Howard Miabach.
264		1	_aCham _bSpringer _c2017.
300			_a1 recurso en línea (154 páginas)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
500			_a5.1.4 Suction Blister.
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
505	0		_aDedication; Preface; Acknowledgements; Contents; Chapter 1: Introduction; 1.1 Developing a New Medicine; 1.2 Key Risks at the Candidate Selection Stage; 1.3 Attrition in the Pharmaceutical Industry; 1.4 Evolution of the Pharma R & D Over the Last Two Decades; 1.5 Pharma R & D Productivity in Decline; 1.6 Cost of Pharma R & D and Cost Up to Candidate Selection; 1.7 Increased Risks in Developing a Topical Drug; 1.8 Increased Opportunities to Develop a Topical Drug; References; Chapter 2: Choosing Topical Drug Candidate: Historical Overview.
505	8		_a2.1 The Pragmatic Topical Drug Development Approach: An Existing Oral/Systemic Drug is Further Developed as a Topical2.1.1 Local Anaesthetics (<1900); 2.1.2 Corticosteroids (1952); 2.1.3 Retinoids (1962); 2.1.4 Antifungals (1967); 2.1.5 NSAIDS (1971); 2.1.6 Antivirals (1983); 2.1.7 Vitamin D3 Derivatives (Late 1980s); 2.1.8 Immunosuppressors (1992); 2.1.9 Summary; 2.2 Moving towards Improved Topical Drug Candidate Selection Processes: Use of In Vivo Models; 2.2.1 The Particular Case of Corticosteroids: Use of Human Models (Early 1960s); 2.2.2 Topical Rodent Models (1960s).
505	8		_a2.2.3 Combined Use of Topical Models and Systemic Rodent Models (1980s)2.2.4 Use of Topical Pig Models (1990s); 2.3 Historical Topical Drug Candidate Selection Summary; References; Chapter 3: Key Factors Affecting the Efficacy of a Topical Drug Candidate: Learnings from Past Topical Drug Development; 3.1 Skin Barrier Condition vs. "Easiness" of Topical Drug Development; 3.1.1 Skin and Its Barrier; 3.1.2 Skin Disease, Target Site in Skin and Skin Barrier Properties; 3.1.3 Success Rate of First in Class Topical Drugs; 3.1.3.1 Easy Development Drug Class; 3.1.3.2 Difficult Development Drug Class.
505	8		_a3.1.4 Summary of Impact of Skin Disease, Its Target Site, Its Barrier and Success Rate of Topical Drug Development3.2 Drug Potency and Clinical Efficacy; References; Chapter 4: Topical Versus Oral/Systemic Drug Discovery; 4.1 Drug Discovery Evolution; 4.2 Oral/Systemic Drug Discovery; 4.3 Topical Drug Discovery; 4.4 Two Key Differences in Discharging Risk in Between the Oral/Systemic and Topical Drug Discovery Processes; 4.4.1 Defining Target Tissue (Skin) Concentration; 4.4.2 Checking that Pharmacokinetic Parameters Are Appropriate; 4.4.2.1 Bioavailability and Delivery Rate.
505	8		_a4.4.2.2 Concept of "Half-Life" in Topical Therapy4.5 Consequences for Preclinical Stage: "Maximising Percutaneous Flux"; 4.6 Learnings from the Oral Drug Development Process; References; Chapter 5: Assessing Drug Concentration in Skin: Direct and Indirect Methods; 5.1 Direct Methods; 5.1.1 Tape Stripping (Vitro/Vivo); 5.1.1.1 Description + Use of Method; 5.1.1.2 Pros; 5.1.1.3 Cons; 5.1.2 Skin Biopsy; 5.1.2.1 Description + Use of Method; 5.1.2.2 Pros; 5.1.2.3 Cons; 5.1.3 In Vitro Percutaneous Studies: Skin Tissue Concentration; 5.1.3.1 Description + Use of Method; 5.1.3.2 Pros; 5.1.3.3 Cons.
520	3		_aThe authors show how the pharmaceutical industry faces the development of dermal drugs and provide the only book of its kind that describes how the industry develops and selects dermal drugs, complete with the challenges and opportunities of the field. Delivery of drugs through the skin has been an attractive and challenging area for research, and advances in modern technologies have resulted in a larger number of drugs being delivered transdermally, including conventional hydrophobic small molecule drugs, hydrophilic drugs and macromolecules. Offering the perspective from the industrial side of selection and development of drugs, the primary audience is geared towards the pharmaceutical industry but can also offer valuable information to clinicians, compounding pharmacists, and similarly pharmacy students. Dermal Drug Selection and Development covers the scientific gaps that exist in terms of dermal pharmacokinetics and the resulting uncertainty by clinicians when choosing a drug candidate.
650		7	_aTerapia transdérmica _2embne _0(OCoLC)fst01154570 _0 _9164420
700	1		_aMaibach, Howard I. _937880
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-59504-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017D
998			_b02/2018 _dz _e- _zSI
999			_c96410 _d96410 _x1